Erythromycin Delayed-Release Tablets 333mg from Canada
Enteric-coated delayed-release tablets with 333mg erythromycin base to protect gastric mucosa, for duodenal ulcer treatment in retail bottles. HTS 3004.20.0020 covers formulated antibiotic dosage forms regardless of release mechanism.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Dissolution profile testing per USP; acid resistance certification
• DESI compliance for older antibiotics
• Avoid moisture during shipping